Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CapSul: Sunitinib and Capecitabine for HCC
NCT00787787Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Sep 2008
- Primary completion
- Apr 2010
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib, capecitabine in hepatocellular carcinoma (HCC), sponsored by University of Washington. Started Sep 2008; status: terminated.
02
Drugs
sunitinibcapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00787787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787787.